ClinicalTrials.gg
CompletedNCT03003884Updated Sep 8, 2017

A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

A Phase 2 interventional study of Remimazolam Tosilate and Propofol in Sedation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-09-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as a procedural sedative during a diagnostic upper GI endoscopy and to assess its efficacy and safety profile comparing to propofol.

Read the detailed description

This is an multi-center,single-blinded,parallel-group,dose-finding study using Remimazolam or propofol for sedation in patients undergoing diagnostic upper GI endoscopy.Subjects are randomized to different treatment groups (including 4 for Remimazolam Tosilate and 1 for propofol).Lidocaine and fentanyl are permitted during a diagnostic upper GI endoscopy.Efficacy and safety profiles of Remimazolam Tosilate are to be evaluated.

02

Conditions studied

  • Sedation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects aged 18-60 years;
  • intending to undergo diagnostic upper GI endoscopy
  • Physical Status Score (ASA PS) I or II;
  • 18 kg/m²\<(Body Mass Index)\<30 kg/m².

Exclusion criteria

Exclusion Criteria:

  • Patients with a suspected upper GI bleed an conditions predisposing to hemorrhage at the discretion of the investigator;
  • one or more of the laboratory findings fall out of the limitations for this study(,,,etc.);
  • history of recent use of narcotics,analgesics,anaesthetics and benzodiazepine hypnotics;
  • history of severe cardiovascular disease;
  • cerebral disease or mental disorder;
  • allergic to drugs used in the study;
  • pregnant women or those in lactation period
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosilate 1

    IV of Remimazolam Tosilate at 5mg for initial dose

    Drug: Remimazolam Tosilate

  • Experimental
    Remimazolam Tosilate 2

    IV of Remimazolam Tosilate at 7mg for initial dose

    Drug: Remimazolam Tosilate

  • Experimental
    Remimazolam Tosilate 3

    IV of Remimazolam Tosilate at 8mg for initial dose

    Drug: Remimazolam Tosilate

  • Experimental
    Remimazolam Tosilate 4

    IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.

    Drug: Remimazolam Tosilate

  • Active comparator
    Propofol

    IV of Propofol at 1.5mg/kg for initial dose

    Drug: Propofol

Interventions

06

What researchers measure

Primary outcomes

  1. successful sedation rate as measured by the proportion of subjects who experienced successful sedation during diagnostic upper GI endoscopy.

    Time frame: From start of study drug injection to patient discharge (approx. 3 hours)

Secondary outcomes

  1. recovery time as measured by time

    Time frame: After the last of study drug injection to patient discharge (approx. 3 hours)

  2. rate of hypotension as measured by the proportion of subjects who experienced hypotension during a diagnostic upper GI endoscopy

    Time frame: From start of study drug injection to patient discharge (approx. 3 hours)

  3. rate of hypoxaemia as measured by the proportion of subjects who experienced hypoxaemia during a diagnostic upper GI endoscopy

    Time frame: From start of study drug injection to patient discharge (approx. 3 hours)

  4. rate of respiratory depression as measured by the proportion of subjects who experienced respiratory depression during a diagnostic upper GI endoscopy

    Time frame: From start of study drug injection to patient discharge (approx. 3 hours)

  5. pain on injection was assessed by the patient immediately after administration of the study drug

    Time frame: 1-10 minutes (from the beginning of sedation )]

07

Study locations

1 site
  • Beijing Union Medical College Hospital
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Dec 28, 2016
Start
Nov 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Sep 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03003884
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Nov 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Sep 8, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion